These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 16142802)

  • 1. Use of abciximab prevents microcirculatory impairment in patients treated with coronary angioplasty for unstable angina: results of a prospective randomized study.
    Prati F; Kwiatkowski P; Caroselli C; Imola F; Manzoli A; Fouad T; Corvo P; Ramazzotti V
    Catheter Cardiovasc Interv; 2005 Oct; 66(2):165-9. PubMed ID: 16142802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preservation of myocardial microcirculation during mechanical reperfusion for myocardial ischemia with either abciximab or eptifibatide.
    Stoupakis G; Orlando J; Kalia H; Skurnick J; Saric M; Arora R
    J Invasive Cardiol; 2003 Sep; 15(9):476-80. PubMed ID: 12947204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microvascular obstruction in acute coronary syndromes: onward to a new therapeutic target.
    Schwartz RS
    Catheter Cardiovasc Interv; 2005 Oct; 66(2):170-2. PubMed ID: 16142803
    [No Abstract]   [Full Text] [Related]  

  • 4. Assessment of coronary angiograms prior to and after treatment with abciximab, and the outcome of angioplasty in refractory unstable angina patients. Angiographic results from the CAPTURE trial.
    van den Brand M; Laarman GJ; Steg PG; De Scheerder I; Heyndrickx G; Beatt K; Kootstra J; Simoons ML
    Eur Heart J; 1999 Nov; 20(21):1572-8. PubMed ID: 10529325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency and efficacy of glycoprotein IIb/IIIa therapy for treatment of threatened or acute vessel closure in 1332 patients undergoing percutaneous transluminal coronary angioplasty.
    Haase KK; Mahrholdt H; Schröder S; Baumbach A; Oberhoff M; Herdeg C; Karsch KR
    Am Heart J; 1999 Feb; 137(2):234-40. PubMed ID: 9924156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT).
    Islam MA; Blankenship JC; Balog C; Iliadis EA; Lincoff AM; Tcheng JE; Califf RM; Topol EJ;
    Am J Cardiol; 2002 Nov; 90(9):916-21. PubMed ID: 12398954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of infarct-related coronary artery patency and microcirculatory function after facilitated percutaneous primary coronary angioplasty: the FINESSE-ANGIO (Facilitated Intervention With Enhanced Reperfusion Speed to Stop Events-Angiographic) study.
    Prati F; Petronio S; Van Boven AJ; Tendera M; De Luca L; de Belder MA; Galassi AR; Imola F; Montalescot G; Peruga JZ; Barnathan ES; Ellis S; Savonitto S;
    JACC Cardiovasc Interv; 2010 Dec; 3(12):1284-91. PubMed ID: 21232723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet glycoprotein IIb/IIIa receptor blockade and coronary resistance in unstable angina.
    Marzilli M; Sambuceti G; Testa R; Fedele S
    J Am Coll Cardiol; 2002 Dec; 40(12):2102-9. PubMed ID: 12505220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized early versus late abciximab in acute myocardial infarction treated with primary coronary intervention (RELAx-AMI Trial).
    Maioli M; Bellandi F; Leoncini M; Toso A; Dabizzi RP
    J Am Coll Cardiol; 2007 Apr; 49(14):1517-24. PubMed ID: 17418289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators.
    Hamm CW; Heeschen C; Goldmann B; Vahanian A; Adgey J; Miguel CM; Rutsch W; Berger J; Kootstra J; Simoons ML
    N Engl J Med; 1999 May; 340(21):1623-9. PubMed ID: 10341274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis.
    Claeys MJ; Van der Planken MG; Bosmans JM; Michiels JJ; Vertessen F; Van Der Goten P; Wuyts FL; Vrints CJ
    Eur Heart J; 2005 Mar; 26(6):567-75. PubMed ID: 15618034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction.
    Costantini CO; Stone GW; Mehran R; Aymong E; Grines CL; Cox DA; Stuckey T; Turco M; Gersh BJ; Tcheng JE; Garcia E; Griffin JJ; Guagliumi G; Leon MB; Lansky AJ
    J Am Coll Cardiol; 2004 Jul; 44(2):305-12. PubMed ID: 15261923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study.
    Lancet; 1997 May; 349(9063):1429-35. PubMed ID: 9164316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical impact of abciximab on long-term outcome after complex coronary angioplasty.
    Wijpkema JS; Jessurun GA; Van Boven AJ; Versteeg DI; Hautvast RW; Tio RA
    Catheter Cardiovasc Interv; 2003 Nov; 60(3):339-43. PubMed ID: 14571484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction.
    Stone GW; Grines CL; Cox DA; Garcia E; Tcheng JE; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Carroll JD; Rutherford BD; Lansky AJ;
    N Engl J Med; 2002 Mar; 346(13):957-66. PubMed ID: 11919304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of primary percutaneous transluminal coronary angioplasty plus abciximab with or without stenting for acute myocardial infarction complicated by cardiogenic shock.
    Giri S; Mitchel J; Azar RR; Kiernan FJ; Fram DB; McKay RG; Mennett R; Clive J; Hirst JA
    Am J Cardiol; 2002 Jan; 89(2):126-31. PubMed ID: 11792329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty.
    Wöhrle J; Grebe OC; Nusser T; Al-Khayer E; Schaible S; Kochs M; Hombach V; Höher M
    Circulation; 2003 Apr; 107(14):1840-3. PubMed ID: 12682003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early abciximab administration in acute myocardial infarction treated with primary coronary intervention.
    Bellandi F; Maioli M; Leoncini M; Toso A; Dabizzi RP
    Int J Cardiol; 2006 Mar; 108(1):36-42. PubMed ID: 15927285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of platelet glycoprotein IIb/IIIa Inhibition on the paclitaxel-eluting stent in patients with stable or unstable angina pectoris or provocable myocardial ischemia (a TAXUS IV substudy).
    Teirstein PS; Kao J; Watkins M; Tannenbaum MA; Laufer N; Chang M; Mehran R; Dangas G; Russell ME; Ellis SG; Stone GW
    Am J Cardiol; 2005 Aug; 96(4):500-5. PubMed ID: 16098300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
    Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
    N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.